Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Medication, Surgery, Others), By Diagnosis (Cornea Examination and Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count, Others), By End-Users (Hospital, Specialty Clinics, Homecare, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032Industry: Healthcare
Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Insights Forecasts to 2030
- The Global Fuchs Endothelial Corneal Dystrophy Market Size was valued at USD 170 Billion in 2022.
- The Market is growing at a CAGR of 7.7% from 2022 to 2032.
- The Worldwide Fuchs Endothelial Corneal Dystrophy Market size is expected to reach USD 360 Billion by 2032.
- Europe is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global Fuchs Endothelial Corneal Dystrophy Market Size is expected to reach USD 360 Billion by 2032, at a CAGR of 7.7% during the forecast period 2022 to 2032. Trauma to the eye, such as from surgery or injury, can also contribute to the development of fuchs endothelial corneal dystrophy market.
A different term for corneal degeneration is fuchs endothelial corneal dystrophy (FECD). The thin cell layer that lines the tissue layer's posterior portion is impacted. This layer is commonly referred to as the endothelium. Illness develops immediately when these cells start to disappear. The cells help the tissue layer to be cleared of extra fluid. The tissue layer is filled with fluid as more cells degenerate, causing swelling and a cloudy cornea. Fuchs endothelial dystrophy is a form of endothelium dystrophy that impacts the tissue layer on the front surface of the attention. Asymmetrical, bilateral, slowly progressing corneal edema is a hallmark of Fuchs Endothelial Corneal Dystrophy in elderly people. Currently, there are several treatment options available for FECD, including medications, corneal transplantation, and Descemet membrane endothelial keratoplasty (DMEK). Corneal transplantation is the most commonly used treatment for fuchs endothelial corneal dystrophy and accounts for the majority of the market share. However, DMEK is gaining popularity due to its superior outcomes and lower risk of rejection.
This research report categorizes the global fuchs endothelial corneal dystrophy market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global fuchs endothelial corneal dystrophy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global fuchs endothelial corneal dystrophy market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Report Coverage
|Market Size in 2022:||USD 170 Billion|
|Forecast Period 2022-2032 CAGR:||7.7%|
|2032 Value Projection:||USD 360 Billion|
|Historical Data for:||2018-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Treatment, By Diagnosis, By End-Users, By Region|
|Companies Covered:||Kowa Company, Ltd., Trefoil Therapeutics, AERIE PHARMACEUTICALS, INC., Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc, Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novartis AG|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Several driving factors drives the fuchs endothelial corneal dystrophy market such as fuchs endothelial corneal dystrophy usually occurs in people over the age of 50, with a higher incidence in women than men. Also, the rise in the research on cellular therapeutic approaches and growing demand for eye care will provide beneficial opportunities for the Fuchs’ endothelial corneal dystrophy market in the forecast period. In addition, fuchs endothelial corneal dystrophy is an inherited disorder, and certain genetic mutations have been identified as contributing factors. Exposure to ultraviolet light and oxidative stress have been linked to the development and progression of fuchs endothelial corneal dystrophy. Certain systemic diseases, such as diabetes and hypertension, have been associated with an increased risk of developing fuchs endothelial corneal dystrophy. Moreover, Hormonal changes during pregnancy and menopause have been linked to the development of fuchs endothelial corneal dystrophy.
Many people may not be aware of global fuchs endothelial corneal dystrophy, its symptoms, or the available treatment options. This can delay the diagnosis and treatment of the disease, resulting in further vision impairment and complications. While there are several treatment options available for this disorder, including medications, corneal transplantation, and Descemet membrane endothelial keratoplasty (DMEK), these treatments may not be accessible to everyone due to cost, availability, or suitability. Moreover, some treatment options for this illness, such as corneal transplantation, can carry a risk of complications such as rejection or infection, which can further compromise vision. In some cases, insurance may not cover the cost of treatment for FECD, making it difficult for patients to access the necessary care. Overall, these factors may restrict the growth of fuchs endothelial corneal dystrophy market.
In 2022, the surgery segment is dominating the market with the largest market share during the forecast period.
Based on the treatment, the global fuchs endothelial corneal dystrophy market is segmented into medication, surgery, and others. Among these, the surgery segment is dominating the market during the forecast period due to it is the most commonly used treatment for fuchs endothelial corneal dystrophy and involves replacing the damaged endothelial layer of the cornea with healthy donor tissue. Traditional corneal transplantation involves replacing the entire cornea, while Descemet membrane endothelial keratoplasty (DMEK) involves transplanting only the thin inner layer of the cornea.
In 2022, the cornea examination and grading segment is driving the market with the largest market share over the forecast period.
Based on the diagnosis, the global fuchs endothelial corneal dystrophy market is segmented cornea examination and grading, corneal tomography, corneal pachymetry, corneal cell count, and others. Throughout these segments, cornea examination and grading are holding the largest market share over the forecast period, owing to grading the severity of the disease being crucial for determining the appropriate treatment approach. This involves the use of specialized equipment to examine the cornea and grade the severity of the disease based on factors such as the number of guttae (small bumps) on the cornea and the presence of corneal edema (swelling).
In 2022, the hospital segment is influencing the market share growth during the forecast period.
Based on the end users, the global fuchs endothelial corneal dystrophy market is bifurcated into hospitals, specialty clinics, home care, & others. Among these, the hospital segment is expected to grow the market during the forecast period because the most of patients with advanced fuchs endothelial corneal dystrophy require surgical treatment, which is typically performed in a hospital setting.
Regional Segment Analysis of the fuchs endothelial corneal dystrophy market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share over the forecast period
Get more details on this report -
North America is dominating the market growth of fuchs endothelial corneal dystrophy due to there being many significant key players present, people having a lot of money to spend, and the healthcare system being well-established. There are people of all ages in this multi-screen universe, so the use of a computer or digital screens may cause users to blink less, which could exacerbate the symptoms of Fuchs Endothelial Corneal Dystrophy (FECD). This could increase the demand for better and more efficient FECD treatments, which is expected to drive the growth in the north america region analyzed.
Europe is the leading market for fuchs endothelial corneal dystrophy, and it will continue to grow shortly due to the availability of various treatment options and prevention strategies, as well as the growing influence of organ donation programs and growing government focus on organ donation policies.
The report offers the appropriate analysis of the key organizations/companies involved within the global fuchs endothelial corneal dystrophy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Kowa Company, Ltd.
- Trefoil Therapeutics
- AERIE PHARMACEUTICALS, INC.
- Price Vision Group
- ProQR Therapeutics
- Pfizer Inc.
- GlaxoSmithKline plc
- Bausch Health Companies Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Novartis AG
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In November 2022, Aerie Pharmaceuticals, Inc. has been successfully acquired by Alcon, a leader in worldwide eye care committed to helping people to see brilliantly. Thanks to its expanding portfolio of supplied pharmaceuticals and development pipeline, Alcon is now more prevalent in the ophthalmic pharmaceutical sector.
- September 2022: An exclusive license partnership for ocular endothelial cell regeneration therapy in the region of China was reached by Celregen and Cellusion Inc.
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Fuchs endothelial Corneal Dystrophy Market based on the below-mentioned segments:
Global Fuchs endothelial Corneal Dystrophy Market, By Treatment
Global Fuchs endothelial Corneal Dystrophy Market, By Diagnosis
- Cornea Examination and Grading
- Corneal Tomography
- Corneal Pachymetry
- Corneal Cell Count
Global Fuchs endothelial Corneal Dystrophy Market, By End Users
- Specialty Clinics
Fuchs endothelial Corneal Dystrophy Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?